Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroendocrine tumor markers.

S W Lamberts1, L J Hofland, F R Nobels

  • 1Department of Medicine, University Hospital Dijkzigt, Erasmus University, 40 Dr. Molewaterplein, 3015 GD Rotterdam, The Netherlands. Lamberts@inw3.azr.nl

Frontiers in Neuroendocrinology
|October 6, 2001
PubMed
Summary

Diagnosing neuroendocrine tumors is challenging due to non-specific tumor markers. Combining hormone tests with tissue response offers sensitive and specific diagnostic methods for improved patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Midgut neuroendocrine tumor patients have a depleted gut microbiome with a discriminative signature.

European journal of cancer (Oxford, England : 1990)·2023
Same author

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer.

Reviews in endocrine & metabolic disorders·2020
Same author

The IGF2 methylation score for adrenocortical cancer: an ENSAT validation study.

Endocrine-related cancer·2020
Same author

MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.

Endocrine-related cancer·2019
Same author

Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms.

Endocrine-related cancer·2018
Same author

Disagreement in normative IGF-I levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency.

Clinical endocrinology·2017

Area of Science:

  • Endocrinology
  • Oncology
  • Biochemistry

Background:

  • Traditional tumor markers for neuroendocrine tumors often lack specificity and sensitivity.
  • Circulating markers are frequently found in healthy individuals, complicating early diagnosis.

Purpose of the Study:

  • To evaluate diagnostic strategies for neuroendocrine tumors.
  • To enhance the sensitivity and specificity of diagnostic tests for neuroendocrine tumors.

Main Methods:

  • Assessing hormone measurements combined with tissue responsiveness.
  • Utilizing radioimmunoassays (RIAs) with polyclonal antibodies for hormone detection.
  • Investigating markers like chromogranin A, neuron-specific enolase, and alpha-subunit.
  • Exploring peptide receptor visualization techniques.

Related Experiment Videos

Main Results:

  • Combining hormone levels with tissue response to stimuli (e.g., PTH during hypercalcemia) yields highly sensitive and specific diagnostic tests.
  • RIAs employing polyclonal antibodies improve hormone measurement accuracy.
  • Chromogranin A, neuron-specific enolase, alpha-subunit, and peptide receptor imaging are valuable for diagnosis and follow-up.

Conclusions:

  • Integrated diagnostic approaches improve neuroendocrine tumor detection.
  • Advanced immunoassay techniques and novel markers enhance diagnostic capabilities.
  • These methods are crucial for both neuroendocrine and non-neuroendocrine tumor management.